5

rofecoxib, 4-(4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone.

96. The combination of Claim 90 wherein the cyclooxygenase-2 inhibitor is

4-(5-methyl-3-phenylisoxazol-4-

10 yl)benzenesulfonamide.

- 97. The method of Claim 1 wherein the antineoplastic agent is anastrozole.
- 98. The method of Claim 1 wherein the antineoplastic agent is calcium carbonate.
 - 99. The method of claim 1 wherein the antineoplastic agent is exemestane.
 - 100. The method of claim 44 wherein the antineoplastic agent is exemestane.
- 20 101. The method of claim 90 wherein the antineoplastic agent is exemestane.
 - 102. The method of Claim 44 wherein the combination is administered in a sequential manner.

-234-

103. The method of Claim 44 wherein the combination is administered in a substantially simultaneous manner.

5

15

20

-233-

95. The combination of Claim 90 wherein the cyclooxygenase-2 inhibitor is

rofecoxib, 4-(4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone.

96. The combination of Claim 90 wherein the cyclooxygenase-2 inhibitor is

4-(5-methyl-3-phenylisoxazol-4-

10 yl)benzenesulfonamide.

21. The method of Claim 1 wherein the antineoplastic agent is anastrozole.

92. The method of Claim 1 wherein the antineoplastic agent is calcium carbonate.

25. The method of claim 1 wherein the antineoplastic agent is exemestane.

94. The method of claim 44 wherein the antineoplastic agent is exemestane.

95. The method of claim 90 wherein the antineoplastic agent is exemestane.

98. The method of Claim 44 wherein the combination is administered in a sequential manner.